F
FoRx Therapeutics
Develops first-in-class compounds for cancer treatment
About FoRx Therapeutics
FoRx Therapeutics is a private startup company based in Basel, Switzerland, that operates in the biotech and pharmaceutical industry. The company's primary focus is on the development of first-in-class compounds for cancer treatment. In simpler terms, FoRx Therapeutics is working on creating new, unique drugs to treat cancer.
Read full description
The company's approach to cancer treatment is innovative and unique. It targets key molecular targets involved in DNA replication stress. DNA replication stress is a state where the DNA replication process is disturbed, which can lead to the development of cancer. By targeting these molecular targets, FoRx Therapeutics aims to develop drugs that can effectively treat cancer.
FoRx Therapeutics' team comprises scientists and advisors with over 20 years of experience in DNA replication stress and DNA Damage Response pathways. These are areas of study that are crucial in understanding how cancer develops and how it can be treated. The team's expertise also extends to cancer biology, cancer genomics, biochemistry, medicinal chemistry, and small molecule drug discovery.
The company's business model is centered around the research, development, and eventual commercialization of these anticancer drugs. As a biotech startup, FoRx Therapeutics likely generates revenue through a combination of research grants, private funding, and potential licensing deals or partnerships with larger pharmaceutical companies.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Basel, Switzerland
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 74.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | $50M | $200M | EQT Life Sciences · M Ventures · Novartis Venture Fund · Pfizer Ventures | ↗ |
| SEEDOther financing | Apr 2020 | $11M | $44M | EQT Life Sciences · Omega Funds · Novartis Venture Fund · M Ventures | ↗ |
Growth signals
Latest recorded traffic for FoRx Therapeutics is 2.6K monthly website visits, up 85.7% over the last three months. FoRx Therapeutics's team declined 2.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
M Ventures
EQT Life Sciences
Omega Funds
Novartis Venture Fund- PVPfizer Ventures
Other known investors1 additional known investor
University of Geneva
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about FoRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FoRx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.